Senti Biosciences - SNTI Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $12.00
  • Forecasted Upside: 181.03 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$4.27
▼ -0.87 (-16.93%)

This chart shows the closing price for SNTI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Senti Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SNTI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SNTI

Analyst Price Target is $12.00
▲ +181.03% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Senti Biosciences in the last 3 months. The average price target is $12.00, with a high forecast of $12.00 and a low forecast of $12.00. The average price target represents a 181.03% upside from the last price of $4.27.

This chart shows the closing price for SNTI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 contributing investment analysts is to buy stock in Senti Biosciences.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/13/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/12/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/10/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/8/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/8/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/7/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/5/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/5/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/29/2022Bank of AmericaInitiated CoverageBuyLow
9/22/2022Chardan CapitalInitiated CoverageBuy$12.00Low
(Data available from 10/5/2017 forward)

News Sentiment Rating

0.13 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/9/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/8/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/8/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/7/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/7/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/6/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/5/2022
  • 0 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/5/2022

Current Sentiment

  • 0 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Senti Biosciences logo
Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate acute myeloid leukemia cells, while sparing the healthy bone marrow; and SENTI-301, a multi-armed off-the-shelf CAR-NK cell therapy designed for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated (NOT) off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer cells, while sparing healthy cells in the body. The company was incorporated in 2016 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $4.27
Low: $3.57
High: $4.75

50 Day Range

MA: $2.08
Low: $1.23
High: $5.14

52 Week Range

Now: $4.27
Low: $1.20
High: $10.35

Volume

88,072 shs

Average Volume

7,052,996 shs

Market Capitalization

$186.86 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.54

Frequently Asked Questions

What sell-side analysts currently cover shares of Senti Biosciences?

The following Wall Street research analysts have issued reports on Senti Biosciences in the last year: Bank of America Co., and Chardan Capital.
View the latest analyst ratings for SNTI.

What is the current price target for Senti Biosciences?

1 Wall Street analysts have set twelve-month price targets for Senti Biosciences in the last year. Their average twelve-month price target is $12.00, suggesting a possible upside of 133.5%. Chardan Capital has the highest price target set, predicting SNTI will reach $12.00 in the next twelve months. Chardan Capital has the lowest price target set, forecasting a price of $12.00 for Senti Biosciences in the next year.
View the latest price targets for SNTI.

What is the current consensus analyst rating for Senti Biosciences?

Senti Biosciences currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SNTI will outperform the market and that investors should add to their positions of Senti Biosciences.
View the latest ratings for SNTI.

What other companies compete with Senti Biosciences?

How do I contact Senti Biosciences' investor relations team?

Senti Biosciences' physical mailing address is 2875 EL CAMINO REAL, REDWOOD CITY CA, 94061. The company's listed phone number is (650) 382-3281 and its investor relations email address is [email protected] The official website for Senti Biosciences is www.sentibio.com. Learn More about contacing Senti Biosciences investor relations.